Thomas Joseph Russo has sold ICVX and made no open-market buys since Aug 2023

Thomas Joseph Russo is a corporate finance executive and Chief Financial Officer of Icosavax, Inc. (ICVX), a Seattle-based biotechnology company developing virus-like particle (VLP) vaccines for infectious diseases.( He was appointed CFO of Icosavax in 2021, bringing more than 25 years of industry experience in finance and operations, and has since served as a reporting insider in connection with multiple equity transactions in Icosavax shares.( According to SEC-linked ownership data, Russo has executed several Form 4-reported trades in Icosavax stock, reflecting his role as a senior financial officer and corporate insider.(

Prior to joining Icosavax, Russo served as Chief Financial Officer of Assembly Biosciences, Inc. (ASMB), a clinical-stage, publicly traded biotechnology company, where he helped raise more than $220 million in gross proceeds through capital markets and non-dilutive financing sources.( Earlier, he spent seven years at Gilead Sciences, Inc., including as Vice President, Head of Commercial Finance, supporting a $20–30 billion revenue business and multibillion-dollar budgets across North America, Europe, Asia, and emerging markets.( His earlier career included work as an Equity Research Senior Analyst covering biotechnology at investment bank Robert W. Baird & Co., where he advised institutional investors and earned Wall Street Journal “Best on the Street” recognition, as well as roles of increasing responsibility in the manufacturing division at Merck & Co., Inc. with a focus on vaccines.( Russo holds a B.S. in biological sciences from the University of Notre Dame and an MBA from the University of Chicago Booth School of Business, and is a CFA charterholder.(

Written by Perplexity from public sources.